Rhenman & Partners Asset Management AB - NEKTAR THERAPEUTICS ownership

NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 208 filers reported holding NEKTAR THERAPEUTICS in Q3 2017. The put-call ratio across all filers is 0.25 and the average weighting 0.2%.

Quarter-by-quarter ownership
Rhenman & Partners Asset Management AB ownership history of NEKTAR THERAPEUTICS
ValueSharesWeighting
Q4 2022$1,243,000
-39.9%
550,0000.0%0.13%
-40.1%
Q3 2022$2,068,000
-1.1%
550,0000.0%0.22%
-8.4%
Q2 2022$2,090,000
-36.8%
550,000
-10.4%
0.24%
-27.3%
Q1 2022$3,309,000
-75.1%
613,884
-35.4%
0.33%
-63.1%
Q4 2021$13,300,000
-22.0%
950,0000.0%0.88%
-26.2%
Q3 2021$17,062,000
+4.7%
950,0000.0%1.20%
+8.2%
Q2 2021$16,302,000
-37.6%
950,000
-27.3%
1.11%
-39.3%
Q1 2021$26,144,000
+13.9%
1,307,196
-3.2%
1.82%
-2.6%
Q4 2020$22,950,000
+38.3%
1,350,000
+35.0%
1.87%
+26.9%
Q3 2020$16,590,000
-9.3%
1,000,000
+26.6%
1.48%
-25.4%
Q2 2020$18,296,000
-4.7%
790,000
-26.5%
1.98%
-26.5%
Q1 2020$19,189,000
-19.2%
1,075,000
-2.3%
2.69%
+3.3%
Q4 2019$23,744,000
+8.6%
1,100,000
-8.3%
2.60%
-5.0%
Q3 2019$21,858,000
-15.3%
1,200,000
+65.5%
2.74%
-3.6%
Q2 2019$25,796,000
+4.5%
725,000
-1.3%
2.84%
-1.6%
Q1 2019$24,677,000
+45.8%
734,445
+42.6%
2.89%
+49.1%
Q4 2018$16,928,000
-9.1%
515,000
+68.6%
1.94%
+3.8%
Q3 2018$18,617,000
-38.3%
305,393
-50.6%
1.86%
-39.6%
Q2 2018$30,160,000
+36.8%
617,652
+197.7%
3.09%
+13.6%
Q1 2018$22,044,000
+4.4%
207,458
-41.3%
2.72%
-4.8%
Q4 2017$21,111,000
+1.5%
353,503
-59.2%
2.85%
+7.5%
Q3 2017$20,789,000
+33.8%
866,194
+9.0%
2.65%
+18.9%
Q2 2017$15,542,000
+40.9%
795,000
+69.1%
2.23%
+27.8%
Q1 2017$11,031,000
+119.3%
470,000
+14.6%
1.75%
+81.2%
Q4 2016$5,031,000
-99.9%
410,000
+5.1%
0.96%
-9.4%
Q3 2016$6,700,200,000
+100082.4%
390,000
-17.0%
1.06%
-10.4%
Q2 2016$6,688,000
-7.4%
470,000
-10.5%
1.19%
-17.1%
Q1 2016$7,219,000
-26.3%
525,000
-9.6%
1.43%
-3.2%
Q4 2015$9,790,000
+29.8%
581,000
-15.6%
1.48%
+23.1%
Q3 2015$7,540,000
-35.7%
688,000
-26.6%
1.20%
-14.6%
Q2 2015$11,722,000
+6.9%
937,000
-6.0%
1.41%
-23.9%
Q1 2015$10,963,000
+197.2%
996,600
+318.7%
1.85%
+73.0%
Q4 2014$3,689,000
-39.8%
238,000
-53.1%
1.07%
-40.4%
Q3 2014$6,132,000
+84.0%
508,000
+95.4%
1.80%
+81.5%
Q2 2014$3,333,000
+51.3%
260,000
+43.0%
0.99%
+49.6%
Q1 2014$2,203,000
+2.1%
181,797
-4.3%
0.66%
-21.7%
Q4 2013$2,157,000190,0000.84%
Other shareholders
NEKTAR THERAPEUTICS shareholders Q3 2017
NameSharesValueWeighting ↓
Cormorant Asset Management, LP 1,828,400$89,281,0006.61%
Cormorant Asset Management, LP 1,500,000$73,245,0005.42%
Camber Capital Management LP 2,000,000$97,660,0003.76%
Rhenman & Partners Asset Management AB 617,652$30,160,0003.09%
BRIDGER MANAGEMENT, LLC 1,134,414$55,393,0003.00%
First Light Asset Management, LLC 374,251$18,275,0002.84%
Gs Investments, Inc. 54,000$2,636,820,0001.97%
SABBY MANAGEMENT, LLC 241,922$11,813,0001.82%
QUANTRES ASSET MANAGEMENT Ltd 50,000$2,441,0001.41%
Tibra Equities Europe Ltd 173,183$8,457,0001.27%
View complete list of NEKTAR THERAPEUTICS shareholders